Your browser doesn't support javascript.
loading
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
Gómez-Miragaya, Jorge; Díaz-Navarro, Ander; Tonda, Raul; Beltran, Sergi; Palomero, Luis; Palafox, Marta; Dobrolecki, Lacey E; Huang, Chen; Vasaikar, Suhas; Zhang, Bing; Wulf, Gerburg M; Collado-Sole, Alejandro; Trinidad, Eva M; Muñoz, Purificación; Paré, Laia; Prat, Aleix; Bruna, Alejandra; Caldas, Carlos; Arribas, Joaquín; Soler-Monso, María Teresa; Petit, Anna; Balmaña, Judith; Cruz, Cristina; Serra, Violeta; Pujana, Miguel Angel; Lewis, Michael T; Puente, Xose S; González-Suárez, Eva.
Afiliación
  • Gómez-Miragaya J; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Díaz-Navarro A; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), CIBERONC, Universidad de Oviedo, Oviedo, Spain.
  • Tonda R; CNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST), Centre for Genomic Analysis (CNAG), Barcelona, Spain.
  • Beltran S; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Palomero L; CNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST), Centre for Genomic Analysis (CNAG), Barcelona, Spain.
  • Palafox M; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Dobrolecki LE; Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Huang C; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Vasaikar S; Departments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Zhang B; Departments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Wulf GM; Departments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Collado-Sole A; Departments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Trinidad EM; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Muñoz P; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Paré L; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Prat A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Bruna A; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Caldas C; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Arribas J; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
  • Soler-Monso MT; Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Petit A; Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Balmaña J; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Cruz C; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
  • Serra V; Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
  • Pujana MA; Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
  • Lewis MT; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Puente XS; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • González-Suárez E; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Cancer Res ; 79(16): 4258-4270, 2019 08 15.
Article en En | MEDLINE | ID: mdl-31213465
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 12 / Carboplatino / Resistencia a Antineoplásicos / Neoplasias de la Mama Triple Negativas / Docetaxel Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 12 / Carboplatino / Resistencia a Antineoplásicos / Neoplasias de la Mama Triple Negativas / Docetaxel Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos